Peihao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peihao Liu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Yingying Qin
Department of Reproductive Medicine, Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
4 shared publications - Xue Jiao
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, the Second Hospital, Shandong University, Jinan, China
3 shared publications - Linlin Cui
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, China
2 shared publications Runxin Yao
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, the Second Hospital, Shandong University, Jinan, China
2 shared publicationsShuxin Ma
2 shared publicationsSiyuan Li
Institute of Women, Children and Reproductive Health, Shandong University , Jinan, Shandong, 250012
2 shared publications
Latest Publications
- 13 May 2026
- Published by Springer Nature in Phenomics
- Vol. 6 (3) , 321-331
Cohort Profile: The Chinese Ovarian Aging Cohort (COACH)
- 13 May 2026
- Published by Springer Nature in Phenomics
- Vol. 6 (3) , 321-331
Cohort Profile: The Chinese Ovarian Aging Cohort (COACH)
- Open Access
- 1 February 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-10
Causal Association Between Sleep Traits and Endometriosis: A Mendelian Randomization Study
Previous studies suggested that irregular sleep-wake rhythms increased the risk of endometriosis. Mechanistically, sleep pattern dysregulation may promote the pathogenesis of endometriosis via neuroendocrine disturbances. However, the causal relationship between sleep traits and endometriosis remains unclear. We aim to investigate the potential causal associations between sleep traits and endometriosis, including its specific anatomical subtypes. Two-sample Mendelian Randomization (MR) analyses were conducted. The primary exposure was insomnia, and the secondary exposures were getting up in the morning, nap during day, sleep disorders, chronotype, snoring, short sleep duration, and long sleep duration. The outcomes were endometriosis along with its anatomical subtypes: uterine, ovarian, vaginal, intestinal, peritoneal, and unspecified endometriosis. We applied inverse variance weighted (IVW), weighted median, simple mode, weighted mode, and MR-Egger regression to estimate causal relationships between sleep traits and the risk of endometriosis. Additionally, a series of sensitivity and validation analyses were performed to ensure robustness. For the primary exposure, IVW results suggested that insomnia was significantly associated with elevated risks of endometriosis (OR=1.83, 95% CI: 1.34–2.50), uterine endometriosis (OR=2.22, 95% CI: 1.30–3.80), ovarian endometriosis (OR=1.61, 95% CI: 1.03–2.54), vaginal endometriosis (OR > 1.00, 95% CI: 1.03–3.79) and unspecified endometriosis (OR=2.70, 95% CI: 1.45–5.02). For the secondary exposure, most sleep traits showed no significant associations with endometriosis risk. Our study demonstrated a causal relationship between insomnia and elevated risks of endometriosis across multiple anatomical subtypes. While no significant associations were observed for other sleep traits, the robust link with insomnia highlights the potential clinical value of sleep-focused interventions in mitigating the risk of endometriosis.
- 1 February 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-10
Open AccessCausal Association Between Sleep Traits and Endometriosis: A Mendelian Randomization Study
Previous studies suggested that irregular sleep-wake rhythms increased the risk of endometriosis. Mechanistically, sleep pattern dysregulation may promote the pathogenesis of endometriosis via neuroendocrine disturbances. However, the causal relationship between sleep traits and endometriosis remains unclear. We aim to investigate the potential causal associations between sleep traits and endometriosis, including its specific anatomical subtypes. Two-sample Mendelian Randomization (MR) analyses were conducted. The primary exposure was insomnia, and the secondary exposures were getting up in the morning, nap during day, sleep disorders, chronotype, snoring, short sleep duration, and long sleep duration. The outcomes were endometriosis along with its anatomical subtypes: uterine, ovarian, vaginal, intestinal, peritoneal, and unspecified endometriosis. We applied inverse variance weighted (IVW), weighted median, simple mode, weighted mode, and MR-Egger regression to estimate causal relationships between sleep traits and the risk of endometriosis. Additionally, a series of sensitivity and validation analyses were performed to ensure robustness. For the primary exposure, IVW results suggested that insomnia was significantly associated with elevated risks of endometriosis (OR=1.83, 95% CI: 1.34–2.50), uterine endometriosis (OR=2.22, 95% CI: 1.30–3.80), ovarian endometriosis (OR=1.61, 95% CI: 1.03–2.54), vaginal endometriosis (OR > 1.00, 95% CI: 1.03–3.79) and unspecified endometriosis (OR=2.70, 95% CI: 1.45–5.02). For the secondary exposure, most sleep traits showed no significant associations with endometriosis risk. Our study demonstrated a causal relationship between insomnia and elevated risks of endometriosis across multiple anatomical subtypes. While no significant associations were observed for other sleep traits, the robust link with insomnia highlights the potential clinical value of sleep-focused interventions in mitigating the risk of endometriosis.
- Open Access
- 14 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1) , 259
Influence of COVID-19 on endocrine and metabolic profiles in women with pathological ovarian aging
Numerous studies have explored the impact of coronavirus disease 2019 (COVID-19) on endocrine and metabolic functions, yet research targeting the population with pathological ovarian aging (POA) remains scarce. The aim of our study was therefore to explore the influence of COVID-19 on ovarian function, thyroid function, liver function, and lipid profiles in women with POA. Nested, self-controlled study. This is an observational self-controlled study. 141 women diagnosed with COVID-19 during the study period were recruited from the prospective Chinese Ovarian Aging Cohort (COACH). After being infected with COVID-19, patients with POA presented further reproductive hormone dysregulation as evaluated by significantly decreased estradiol (E2) (22.4 [IQR 7.8–62.1] pg/mL vs. 16.9 [IQR 6.2–51.9] pg/mL, P = 0.034) and inhibin B (INHB) (16.3 [IQR 10.0-23.6] pg/mL vs. 12.3 [IQR 10.0–21.0] pg/mL, P = 0.029) concentrations. In addition, patients with POA may experience thyroid dysfunction, liver dysfunction, and lipid metabolism disorders after SARS-CoV-2 infection, as indicated by significantly decreased triiodothyronine (FT3) levels, and significantly increased aspartate transaminase (AST) and total cholesterol (TC) levels (all P < 0.05). We performed subgroup analyses stratified by age to determine whether POA patients of different age groups exhibit different endocrine and metabolic responses to SARS-CoV-2 infection. The levels of E2 (25.5 [IQR 9.3–77.6] pg/mL vs. 14.6 [IQR 5.1–37.9] pg/mL, P = 0.006) and INHB (16.9 [IQR 10.0-25.1] pg/mL vs. 10.7 [IQR 10.0–22.0] pg/mL, P = 0.012) were significantly decreased after SARS-CoV-2 infection in women younger than 35 years. In both subgroups, the level of FT3 was significantly decreased after SARS-CoV-2 infection, whereas the level of TC was significantly increased after SARS-CoV-2 infection, independent of age (all P < 0.05). This study provides preliminary clinical evidence that patients with POA and confirmed SARS-CoV-2 infection may experience further reproductive hormone dysregulation, along with thyroid dysfunction, liver dysfunction, and lipid disorders, facilitating improved clinical management.
- 14 November 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18 (1) , 259
Open AccessInfluence of COVID-19 on endocrine and metabolic profiles in women with pathological ovarian aging
Numerous studies have explored the impact of coronavirus disease 2019 (COVID-19) on endocrine and metabolic functions, yet research targeting the population with pathological ovarian aging (POA) remains scarce. The aim of our study was therefore to explore the influence of COVID-19 on ovarian function, thyroid function, liver function, and lipid profiles in women with POA. Nested, self-controlled study. This is an observational self-controlled study. 141 women diagnosed with COVID-19 during the study period were recruited from the prospective Chinese Ovarian Aging Cohort (COACH). After being infected with COVID-19, patients with POA presented further reproductive hormone dysregulation as evaluated by significantly decreased estradiol (E2) (22.4 [IQR 7.8–62.1] pg/mL vs. 16.9 [IQR 6.2–51.9] pg/mL, P = 0.034) and inhibin B (INHB) (16.3 [IQR 10.0-23.6] pg/mL vs. 12.3 [IQR 10.0–21.0] pg/mL, P = 0.029) concentrations. In addition, patients with POA may experience thyroid dysfunction, liver dysfunction, and lipid metabolism disorders after SARS-CoV-2 infection, as indicated by significantly decreased triiodothyronine (FT3) levels, and significantly increased aspartate transaminase (AST) and total cholesterol (TC) levels (all P < 0.05). We performed subgroup analyses stratified by age to determine whether POA patients of different age groups exhibit different endocrine and metabolic responses to SARS-CoV-2 infection. The levels of E2 (25.5 [IQR 9.3–77.6] pg/mL vs. 14.6 [IQR 5.1–37.9] pg/mL, P = 0.006) and INHB (16.9 [IQR 10.0-25.1] pg/mL vs. 10.7 [IQR 10.0–22.0] pg/mL, P = 0.012) were significantly decreased after SARS-CoV-2 infection in women younger than 35 years. In both subgroups, the level of FT3 was significantly decreased after SARS-CoV-2 infection, whereas the level of TC was significantly increased after SARS-CoV-2 infection, independent of age (all P < 0.05). This study provides preliminary clinical evidence that patients with POA and confirmed SARS-CoV-2 infection may experience further reproductive hormone dysregulation, along with thyroid dysfunction, liver dysfunction, and lipid disorders, facilitating improved clinical management.
- 20 June 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (6) , 105118
Factors influencing the rate of anti-Müllerian hormone decline: a retrospective study of 4245 infertile women
- 20 June 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (6) , 105118
Factors influencing the rate of anti-Müllerian hormone decline: a retrospective study of 4245 infertile women
- 12 March 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (2) , 104924
Day 3 embryo quality impact on euploidy rate and pregnancy outcomes: a retrospective study of 12,669 PGT-A embryos
- 12 March 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (2) , 104924
Day 3 embryo quality impact on euploidy rate and pregnancy outcomes: a retrospective study of 12,669 PGT-A embryos
- Open Access
- 19 August 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (10) , bvae143
Effects of Metabolic Syndrome on Pregnancy Outcomes in Women Without Polycystic Ovary Syndrome
Context Metabolic syndrome (MetS) is a cluster of metabolic risk factors that predict cardiovascular disease. Previous studies suggested that MetS impaired clinical outcomes in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). Objective To evaluate the effects of MetS on IVF/intracytoplasmic sperm injection (ICSI) outcomes in women without PCOS. Methods This retrospective study collected 8539 eligible women without PCOS who came for their first cycle of IVF/ICSI to the Institute of Women, Children and Reproductive Health, Shandong University, from 2017 to 2020, including 1147 subjects in the MetS group and 7392 in the control group. The primary outcome was live birth. Secondary outcomes included other pregnancy outcomes and the risk of maternal and neonatal complications. Results Women in the MetS group had a lower live birth rate (50.6% vs 54.9%, adjusted odds ratio [aOR] 0.87, 95% CI 0.75-1.00, P = .045) and higher risks of late miscarriage (5.8% vs 3.3%, aOR 1.52, 95% CI 1.02-2.27, P = .041), gestational diabetes mellitus (13.7% vs 7.0%, aOR 1.84, 95% CI 1.30-2.60, P = .001), hypertensive disorder of pregnancy (7.8% vs 3.5%, aOR 1.79, 95% CI 1.14-2.83, P = .012), and preterm birth (9.0% vs 4.4%, aOR 2.03, 95% CI 1.33-3.08, P = .001). Singleton newborns in the MetS group were at higher risk of large for gestational age (33.3% vs 20.5%, aOR 1.66, 95% CI (1.31-2.13), P < .001) but at lower risk of small for gestational age (2.7% vs 6.2%, aOR 0.48, 95% CI 0.25-0.90, P = .023). Conclusion MetS was associated with adverse IVF/ICSI outcomes in women without PCOS.
- 19 August 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (10) , bvae143
Open AccessEffects of Metabolic Syndrome on Pregnancy Outcomes in Women Without Polycystic Ovary Syndrome
Context Metabolic syndrome (MetS) is a cluster of metabolic risk factors that predict cardiovascular disease. Previous studies suggested that MetS impaired clinical outcomes in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). Objective To evaluate the effects of MetS on IVF/intracytoplasmic sperm injection (ICSI) outcomes in women without PCOS. Methods This retrospective study collected 8539 eligible women without PCOS who came for their first cycle of IVF/ICSI to the Institute of Women, Children and Reproductive Health, Shandong University, from 2017 to 2020, including 1147 subjects in the MetS group and 7392 in the control group. The primary outcome was live birth. Secondary outcomes included other pregnancy outcomes and the risk of maternal and neonatal complications. Results Women in the MetS group had a lower live birth rate (50.6% vs 54.9%, adjusted odds ratio [aOR] 0.87, 95% CI 0.75-1.00, P = .045) and higher risks of late miscarriage (5.8% vs 3.3%, aOR 1.52, 95% CI 1.02-2.27, P = .041), gestational diabetes mellitus (13.7% vs 7.0%, aOR 1.84, 95% CI 1.30-2.60, P = .001), hypertensive disorder of pregnancy (7.8% vs 3.5%, aOR 1.79, 95% CI 1.14-2.83, P = .012), and preterm birth (9.0% vs 4.4%, aOR 2.03, 95% CI 1.33-3.08, P = .001). Singleton newborns in the MetS group were at higher risk of large for gestational age (33.3% vs 20.5%, aOR 1.66, 95% CI (1.31-2.13), P < .001) but at lower risk of small for gestational age (2.7% vs 6.2%, aOR 0.48, 95% CI 0.25-0.90, P = .023). Conclusion MetS was associated with adverse IVF/ICSI outcomes in women without PCOS.
- Open Access
- 12 December 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-12
Maternal and neonatal complications after IVF/ICSI-fresh embryo transfer in low-prognosis women under the POSEIDON criteria: a retrospective cohort study
Background: Several studies on pregnancy complications of poor ovarian response (POR) patients did not draw a consistent conclusion. The POSEIDON criteria introduces the concept of “low prognosis” and divides POR patients into four groups based on age, AFC and AMH for individualized management. We analyzed low-prognosis population and patients with regular ovarian response, compared maternal and neonatal complications and discussed the relevant risk factors. Methods: A retrospective cohort study was conducted of females who achieved a singleton clinical pregnancy after IVF / ICSI—fresh embryo transfer in a single center from January 2014 to March 2019. Participants with low prognosis, as defined by the POSEIDON criteria, were enrolled in the study groups. The controls were defined as AFC ≥ five and number of retrieved oocytes > nine. Maternal and neonatal complications were compared among those groups. Results: There were 2554 cycles in POSEIDON group 1, 971 in POSEIDON group 2, 141 in POSEIDON group 3, 142 in POSEIDON group 4, and 3820 in Control. Univariate analysis roughly showed that Groups 2 and 4 had an increased tendency of pregnancy complications. Multi-variable generalized estimating equations (GEE) analysis showed that the risks of GDM, total pregnancy loss, and first-trimester pregnancy loss in Groups 2 and 4 were significantly higher than in Control. The risk of hypertensive disorders of pregnancy (HDP) in Groups 2 and 3 increased, and Group 4 had an increased tendency without statistical significance. After classification by age, GEE analysis showed no significant difference in risks of all complications among groups ≥ 35 years. In patients < 35 years, the risk of HDP in POSEIDON group 3 was significantly higher than in controls (< 35 years), and there was no significant increase in the risk of other complications. Conclusion: Compared to patients with regular ovarian response, low-prognosis population have increased tendency of maternal and neonatal complications. In low-prognosis patients, advanced age (≥ 35 years) might be the predominant risk factor for pregnancy complications. In those < 35 years, poor ovarian reserve could contribute to HDP.
- 12 December 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-12
Open AccessMaternal and neonatal complications after IVF/ICSI-fresh embryo transfer in low-prognosis women under the POSEIDON criteria: a retrospective cohort study
Background: Several studies on pregnancy complications of poor ovarian response (POR) patients did not draw a consistent conclusion. The POSEIDON criteria introduces the concept of “low prognosis” and divides POR patients into four groups based on age, AFC and AMH for individualized management. We analyzed low-prognosis population and patients with regular ovarian response, compared maternal and neonatal complications and discussed the relevant risk factors. Methods: A retrospective cohort study was conducted of females who achieved a singleton clinical pregnancy after IVF / ICSI—fresh embryo transfer in a single center from January 2014 to March 2019. Participants with low prognosis, as defined by the POSEIDON criteria, were enrolled in the study groups. The controls were defined as AFC ≥ five and number of retrieved oocytes > nine. Maternal and neonatal complications were compared among those groups. Results: There were 2554 cycles in POSEIDON group 1, 971 in POSEIDON group 2, 141 in POSEIDON group 3, 142 in POSEIDON group 4, and 3820 in Control. Univariate analysis roughly showed that Groups 2 and 4 had an increased tendency of pregnancy complications. Multi-variable generalized estimating equations (GEE) analysis showed that the risks of GDM, total pregnancy loss, and first-trimester pregnancy loss in Groups 2 and 4 were significantly higher than in Control. The risk of hypertensive disorders of pregnancy (HDP) in Groups 2 and 3 increased, and Group 4 had an increased tendency without statistical significance. After classification by age, GEE analysis showed no significant difference in risks of all complications among groups ≥ 35 years. In patients < 35 years, the risk of HDP in POSEIDON group 3 was significantly higher than in controls (< 35 years), and there was no significant increase in the risk of other complications. Conclusion: Compared to patients with regular ovarian response, low-prognosis population have increased tendency of maternal and neonatal complications. In low-prognosis patients, advanced age (≥ 35 years) might be the predominant risk factor for pregnancy complications. In those < 35 years, poor ovarian reserve could contribute to HDP.
- 8 August 2023
- Published by Taylor & Francis in Human Fertility
- Vol. 26 (4) , 815-823
An appraisal of current embryo transfer strategies
Embryo transfer, one of the most essential procedures in assisted reproductive technology, plays a vital role in the success of in-vitro fertilization and intracytoplasmic sperm injection. During the last decades, the strategies for embryo transfer have changed dramatically. In this review, we evaluate the efficacy and safety of several current embryo transfer strategies including fresh versus frozen embryo transfer, cleavage- versus blastocyst-stage embryo transfer, and single- versus double-embryo transfer. Available evidence indicates that the freeze-only strategy improves the live birth rate after the first embryo transfer in high responders while making no difference in normal responders. The risk of ovarian hyperstimulation syndrome is significantly reduced in the freeze-only strategy. Fresh blastocyst-stage embryo transfer increased live birth rate compared to cleavage-stage embryo transfer. The best embryo transfer strategy is one which tailors to individual circumstances and preferences.
- 8 August 2023
- Published by Taylor & Francis in Human Fertility
- Vol. 26 (4) , 815-823
An appraisal of current embryo transfer strategies
Embryo transfer, one of the most essential procedures in assisted reproductive technology, plays a vital role in the success of in-vitro fertilization and intracytoplasmic sperm injection. During the last decades, the strategies for embryo transfer have changed dramatically. In this review, we evaluate the efficacy and safety of several current embryo transfer strategies including fresh versus frozen embryo transfer, cleavage- versus blastocyst-stage embryo transfer, and single- versus double-embryo transfer. Available evidence indicates that the freeze-only strategy improves the live birth rate after the first embryo transfer in high responders while making no difference in normal responders. The risk of ovarian hyperstimulation syndrome is significantly reduced in the freeze-only strategy. Fresh blastocyst-stage embryo transfer increased live birth rate compared to cleavage-stage embryo transfer. The best embryo transfer strategy is one which tailors to individual circumstances and preferences.
- 1 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (2) , 247-253
Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos
- 1 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (2) , 247-253
Blastocyst euploidy rates in low-prognosis patients according to the POSEIDON criteria: a retrospective analysis of 3016 embryos
- Open Access
- 2 December 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
Background: Poor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed and stratified by the POSEIDON criteria remains indistinct.Methods: This retrospective study was performed among women with POR according to the POSEIDON criteria who failed a previous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle, and the subsequent cycle was under GH cotreatment and conducted within 12 months. These participants were stratified into four groups according to the POSEIDON criteria. The comparison was implemented between the failed cycle and the cycle treated with GH. Generalized estimating equation (GEE) multivariate regression was applied for data analysis.Results: A total of 428 low-prognosis women were included in this study. GH supplementation improved the live birth rates (47.66%, 28.33%, 45.45%, and 24.07%; in groups 1, 2, 3, and 4, respectively) and the clinical pregnancy rates (OR 19.16, 95% CI 7.87–46.63, p < 0.001; OR 7.44, 95% CI 1.65–33.55, p = 0.009; OR 10.19, 95% CI 2.39–43.52, p = 0.002; OR 27.63, 95% CI 4.46–171.11, p < 0.001; in groups 1, 2, 3, and 4, respectively) in all four POSEIDON groups. The number of oocytes retrieved was significantly elevated in the subgroups with normal ovarian reserve (IRR 1.47, 95% CI 1.36–1.59, p < 0.001; IRR 1.31, 95% CI 1.15–1.49, p < 0.001; in groups 1 and 2, respectively). The number of day-3 good-quality embryos was significantly elevated in the subgroups with either normal ovarian reserve or aged young (IRR 2.13, 95% CI 1.78–2.56, p < 0.001; IRR 1.54, 95% CI 1.26–1.89, p < 0.001; IRR 1.47, 95% CI 1.10–1.98, p = 0.010; in groups 1, 2, and 3, respectively).Conclusion: Growth hormone cotreatment could ameliorate the pregnancy outcome for women with POR under the POSEIDON criteria who failed a previous IVF/ICSI cycle. The application of growth hormone for low-prognosis women who experienced a failed cycle might be considered and further studied.
- 2 December 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Open AccessGrowth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
Background: Poor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed and stratified by the POSEIDON criteria remains indistinct.Methods: This retrospective study was performed among women with POR according to the POSEIDON criteria who failed a previous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle, and the subsequent cycle was under GH cotreatment and conducted within 12 months. These participants were stratified into four groups according to the POSEIDON criteria. The comparison was implemented between the failed cycle and the cycle treated with GH. Generalized estimating equation (GEE) multivariate regression was applied for data analysis.Results: A total of 428 low-prognosis women were included in this study. GH supplementation improved the live birth rates (47.66%, 28.33%, 45.45%, and 24.07%; in groups 1, 2, 3, and 4, respectively) and the clinical pregnancy rates (OR 19.16, 95% CI 7.87–46.63, p < 0.001; OR 7.44, 95% CI 1.65–33.55, p = 0.009; OR 10.19, 95% CI 2.39–43.52, p = 0.002; OR 27.63, 95% CI 4.46–171.11, p < 0.001; in groups 1, 2, 3, and 4, respectively) in all four POSEIDON groups. The number of oocytes retrieved was significantly elevated in the subgroups with normal ovarian reserve (IRR 1.47, 95% CI 1.36–1.59, p < 0.001; IRR 1.31, 95% CI 1.15–1.49, p < 0.001; in groups 1 and 2, respectively). The number of day-3 good-quality embryos was significantly elevated in the subgroups with either normal ovarian reserve or aged young (IRR 2.13, 95% CI 1.78–2.56, p < 0.001; IRR 1.54, 95% CI 1.26–1.89, p < 0.001; IRR 1.47, 95% CI 1.10–1.98, p = 0.010; in groups 1, 2, and 3, respectively).Conclusion: Growth hormone cotreatment could ameliorate the pregnancy outcome for women with POR under the POSEIDON criteria who failed a previous IVF/ICSI cycle. The application of growth hormone for low-prognosis women who experienced a failed cycle might be considered and further studied.